Oncotelic identifies four-gene signature linked to liver cancer survival
OTLC•Oncotelic Therapeutics announced a four-gene prognostic signature in liver cancer, supporting patient selection for Sapu003 clinical trials. Its association with survival was independently validated in a Japanese hepatocellular carcinoma cohort of 203 patients.
1. Signature and validation
Oncotelic Therapeutics announced a four-gene prognostic signature in liver cancer to support patient selection for Sapu003 clinical trials. The association between the signature and survival was independently validated in a Japanese hepatocellular carcinoma cohort of 203 patients.
2. Study details
The study, published October 23, 2026, in Biomedicines, combined AI-guided literature analysis using PDAOAI with gene-expression and survival analyses. Sapu003 is an intravenous formulation of everolimus, an mTOR inhibitor.
